The Adalimumab Market is witnessing steady growth as demand for biologic therapies continues to increase across autoimmune and inflammatory diseases. The market is anticipated to reach US$ 42.25 Billion by 2034, registering a CAGR of 5.42% from 2026 to 2034. Increasing prevalence of rheumatoid arthritis, psoriasis, inflammatory bowel disease, and other immune-mediated...